ML can be applied to risk stratification and individualised dosimetry: Yazdani et al combined pre-therapy [68Ga]Ga-PSMA PET/CT radiomics with clinical biomarkers to predict absorbed doses in kidneys and tumours [110]. Here, FOLH1 is linked to neoplasm.